ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
파버병 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 표적 치료제의 파이프라인 확대, 정부 인센티브 및 희귀 의약품 지정 증가, 전문 의료 서비스에 대한 접근성 확대, 희귀 질환에 초점을 맞춘 생명공학 신생 기업에 대한 투자 증가, 차세대 염기서열 분석의 사용 증가에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 유전자 치료 기술의 발전, 희귀 질환 진단을 위한 인공 지능의 통합, 기술 기반의 바이오마커 발견, 효소 대체 요법의 발전, 신생아 선별 검사 프로그램의 개선 등이 있습니다.
희귀 유전 질환의 유병률이 증가함에 따라 향후 몇 년 동안 파버병 시장이 성장할 것으로 예상됩니다. 희귀 유전 질환은 개인의 DNA 돌연변이로 인해 유전되는 질환으로, 인구의 극히 일부에 영향을 미칩니다. 이 유병률의 증가는 주로 진단 기술의 발전으로 인해 이전에는 진단되지 않았거나 잘못 진단된 질환을 조기에 정확히 진단할 수 있게 되었기 때문입니다. 파버 병은 희귀 유전성 질환의 증가를 해결하는 데 중요한 역할을 하며, 초희귀 질환을 위한 효소 대체 치료법 연구를 지원하고 표적 치료법 개발의 모델로 작용합니다. 예를 들어, 2022년 11월 호주 보건 및 노인 돌봄 부서는 희귀 질환(10,000명 중 5명 미만에게 영향을 미치는 질환)이 약 200만 명, 즉 인구의 8%에게 영향을 미치며, 알려진 만성 또는 생명을 위협하는 질환이 7,000종 이상 존재한다고 보고했습니다. 따라서 희귀 유전성 질환의 유병률 증가가 파버 병 시장 확대에 기여하고 있습니다.
임상 시험에 대한 투자 증가로 인해 향후 몇 년 동안 파버병 시장이 성장할 것으로 예상됩니다. 임상 시험은 의약품, 치료법, 의료 기기 등 의료 개입의 안전성, 효과 및 결과를 평가하기 위해 인간을 대상으로 진행하는 연구입니다. 이러한 투자 증가는 의학, 맞춤형 의약품의 발전과 함께 혁신적인 치료법에 대한 수요가 증가하고, 충족되지 않은 의료 과제를 해결해야 할 시급한 필요성이 대두되고 있기 때문입니다. 파버병은 희귀하고 치료가 어려운 유전 질환에 대한 연구의 필요성을 강조함으로써 이러한 투자의 중요성을 강조합니다. 예를 들어, 2024년 10월, 미국에 본사를 둔 제약 정보 솔루션 제공업체인 Citeline은 TrialTrove가 2024년에 시작될 9,959건의 임상 1-3상 임상 시험을 기록했다고 밝혔는데, 이는 2023년에 비해 9.4% 증가한 수치입니다. 따라서 임상 시험에 대한 투자가 증가하면서 파버병 시장이 확대되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 파버병 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 파버병 시장 : 성장률 분석
세계의 파버병 시장 실적 : 규모와 성장(2019-2024년)
세계의 파버병 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 파버병 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 파버병 시장 : 파버병 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
고전적 파버병
비고전적 파버병
세계의 파버병 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
효소 보충 요법
치료
유전자 치료
골수 이식
지지요법
세계의 파버병 시장 : 임상 증상별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
관절의 장애와 변형
난청
호흡곤란
피부 증상
세계의 파버병 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
진단센터
기타 최종 사용자
세계의 파버병 시장 : 고전적 파버병의 병형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1형 중증 유아형
유형 2 중간형 소아형
유형 3 청소년 발병형
세계의 파버병 시장 : 비고전적 파버병의 병형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유형 4 신경 우위형
유형 5 내장 우위형
유형 6 심폐장애 폼
제7장 지역별, 국가별 분석
세계의 파버병 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 파버병 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
파버병 시장 : 경쟁 구도
파버병 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Mount Sinai Health System : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Emory Healthcare
Kyowa Kirin Co. Ltd.
BioMarin Pharmaceutical Inc.
Children's National Hospital
Medanta-The Medicity(Global Health Ltd.)
Amicus Therapeutics Inc.
JCR Pharmaceuticals Co. Ltd.
Spark Therapeutics Inc.
REGENXBIO Inc.
Passage Bio Inc.
Protalix BioTherapeutics Inc.
Medicover Hospitals
Minoryx Therapeutics SL
bluebird bio Inc.
Avrobio Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
파버병 시장(2029년) : 새로운 기회를 제공하는 국가
파버병 시장(2029년) : 새로운 기회를 제공하는 부문
파버병 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Farber's disease is a rare inherited disorder resulting from a deficiency of the enzyme acid ceramidase, which causes fatty substances to build up in body tissues. It is passed down through an autosomal recessive pattern and usually appears during infancy. Common symptoms include joint deformities, subcutaneous nodules, and a gradual decline in neurological function. The disease progresses over time and can be life-threatening, necessitating coordinated care and symptom-focused treatment.
Farber's disease primarily exists in two forms: classical and non-classical. The classical form is the most common type and is marked by early-onset symptoms such as joint abnormalities, subcutaneous nodules, and progressive neurological deterioration. Available treatments include enzyme replacement therapy, gene therapy, symptomatic management, bone marrow transplantation, and supportive interventions for symptoms like joint issues, hearing loss, respiratory problems, and skin-related conditions. Key end-users include hospitals, specialized clinics, diagnostic facilities, and others.
The farber's disease market research report is one of a series of new reports from The Business Research Company that provides farber's disease market statistics, including the farber's disease industry global market size, regional shares, competitors with the farber's disease market share, detailed farber's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the farber's disease industry. This farber's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The farber's disease market size has grown strongly in recent years. It will grow from $1.87 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be credited to increasing awareness and diagnosis rates, greater adoption of genetic testing, a rise in research efforts focused on lysosomal storage disorders, the expansion of rare disease registries, and growing support from patient advocacy organizations.
The farber's disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the expanding pipeline of targeted therapies, increasing government incentives and orphan drug designations, broader access to specialized healthcare services, rising investments in rare disease-focused biotech startups, and the growing use of next-generation sequencing. Key trends expected during this period include progress in gene therapy technologies, the integration of artificial intelligence for diagnosing rare diseases, technology-enabled biomarker discovery, advancements in enzyme replacement therapies, and improvements in newborn screening programs.
The increasing prevalence of rare genetic disorders is anticipated to drive the growth of the Farber's disease market in the coming years. Rare genetic disorders are inherited conditions caused by mutations in an individual's DNA, affecting a very small portion of the population. This rise in prevalence is largely attributed to advancements in diagnostic technologies that allow for earlier and more accurate detection of conditions that were previously undiagnosed or misdiagnosed. Farber's disease plays a significant role in addressing the rise in rare genetic disorders by acting as a model for the development of targeted therapies and supporting research in enzyme replacement treatments for ultra-rare conditions. For example, in November 2022, the Australian Government Department of Health and Aged Care reported that rare diseases-defined as affecting fewer than 5 in 10,000 people-impact around 2 million individuals, or 8% of the population, with over 7,000 known chronic or life-threatening conditions. Hence, the rising prevalence of rare genetic diseases is contributing to the expansion of the Farber's disease market.
The rising investment in clinical trials is expected to drive the growth of the Farber's disease market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, effectiveness, and outcomes of medical interventions, including drugs, treatments, or medical devices. This growing investment is fueled by the increasing demand for innovative therapies, spurred by advancements in medical science, personalized medicine, and the pressing need to address unmet healthcare challenges. Farber's disease underscores the importance of such investments by emphasizing the need for research focused on rare and underserved genetic disorders. For example, in October 2024, Citeline, a US-based provider of pharmaceutical intelligence solutions, reported that TrialTrove recorded 9,959 Phase I-III clinical trials set to begin in 2024 involving at least one drug-a 9.4% rise compared to 2023. Thus, the growing investment in clinical trials is contributing to the expansion of the Farber's disease market.
In September 2022, Idera Pharmaceuticals, a biotechnology company based in the US, acquired Aceragen for an undisclosed sum. This acquisition was intended to strengthen Idera Pharmaceuticals' position in the rare disease market by adding Aceragen's pipeline to its portfolio, including ACG-801, a therapy in development for Farber's disease. The move aims to address a significant unmet medical need and accelerate the advancement of enzyme replacement therapies. Aceragen Inc., also a US-based biopharmaceutical company, is actively developing ACG-801, an enzyme replacement therapy designed specifically to treat Farber disease, a rare lysosomal storage disorder.
Major players in the farber's disease market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Mount Sinai Health System, Emory Healthcare, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Children's National Hospital, Medanta - The Medicity (Global Health Ltd.), Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Spark Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Protalix BioTherapeutics Inc., Medicover Hospitals, Minoryx Therapeutics S.L., bluebird bio Inc., and Avrobio Inc.
North America was the largest region in the farber's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in farber's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the farber's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The farber's disease market includes revenues earned by rehabilitation services, nutritional support services, and clinical trial access services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Farber's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on farber's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for farber's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The farber's disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type Of Farber's Disease: Classical Farber's Disease; Non-Classical Farber's Disease
2) By Treatment: Enzyme Replacement Therapy; Symptomatic Treatment; Gene Therapy; Bone Marrow Transplant; Supportive Care
3) By Clinical Symptoms: Joint Involvement And Deformities; Hearing Loss; Respiratory Distress; Dermatological Manifestations
4 By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users
Subsegments:
1) By Classical Farber's Disease: Type 1 Severe Infantile Form; Type 2 Intermediate Childhood Form; Type 3 Juvenile-Onset Form
2) By Non-Classical Farber's Disease: Type 4 Neurological Predominant Form; Type 5 Visceral Predominant Form; Type 6 Cardiopulmonary Involvement Form
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Mount Sinai Health System
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Farber's Disease Market Characteristics
3. Farber's Disease Market Trends And Strategies
4. Farber's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Farber's Disease Growth Analysis And Strategic Analysis Framework
5.1. Global Farber's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Farber's Disease Market Growth Rate Analysis
5.4. Global Farber's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Farber's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Farber's Disease Total Addressable Market (TAM)
6. Farber's Disease Market Segmentation
6.1. Global Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Classical Farber's Disease
Non-Classical Farber's Disease
6.2. Global Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy
Symptomatic Treatment
Gene Therapy
Bone Marrow Transplant
Supportive Care
6.3. Global Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Joint Involvement And Deformities
Hearing Loss
Respiratory Distress
Dermatological Manifestations
6.4. Global Farber's Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Diagnostic Centers
Other End-Users
6.5. Global Farber's Disease Market, Sub-Segmentation Of Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 1 Severe Infantile Form
Type 2 Intermediate Childhood Form
Type 3 Juvenile-Onset Form
6.6. Global Farber's Disease Market, Sub-Segmentation Of Non-Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 4 Neurological Predominant Form
Type 5 Visceral Predominant Form
Type 6 Cardiopulmonary Involvement Form
7. Farber's Disease Market Regional And Country Analysis
7.1. Global Farber's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Farber's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
